BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain
BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain
复制标题
DOI:
10.1093/brain/awaa332
复制
发表时间:
2020-12-01
期刊:
影响因子:
14.5
通讯作者:
Egan, Michael F.
中科院分区:
文献类型:
--
作者:
Sur, Cyrille;Kost, James;Egan, Michael F.
In the phase 3 EPOCH trial (Clinicaltrials.gov; NCT01739348), treatment with the BACE inhibitor verubecestat failed to improve cognition in patients with mild-to-moderate Alzheimer's disease, but was associated with reduced hippocampal volume after 78 weeks as assessed by MRI. The aims of the present exploratory analyses were to: (i) characterize the effect of verubecestat on brain volume by evaluating the time course of volumetric MRI changes for a variety of brain regions; and (ii) understand the mechanism through which verubecestat might cause hippocampal (and other brain region) volume loss by assessing its relationship to measures of amyloid, neurodegeneration, and cognition. Participants were aged 55-85 years with probable Alzheimer's disease dementia and a Mini Mental State Examination score >= 15 and 0.27). There were no significant differences between verubecestat and placebo in changes from baseline in CSF levels of neurofilament light chain at Week 78 (increases of 7.2 and 14.6 pg/ml for verubecestat versus 19.7 pg/ml for placebo, P-values >= 0.1). There was a moderate correlation between volumetric MRI changes and cognitive decline in all groups including placebo at Week 78 (e.g. r = -0.45 to -0.55, P